Whole-brain radiotherapy and chemotherapy in the treatment of patients with breast cancer and brain metastases

被引:0
|
作者
Xu, Kai [1 ]
Huang, Yong [1 ]
Yao, Junzhong [3 ]
Xu, Zhong [1 ]
He, Xiaofei [2 ]
机构
[1] Jiangsu Prov Corps Hosp Chinese Peoples Armed Pol, Dept Neurosurg, Yangzhou, Jiangsu, Peoples R China
[2] Jiangsu Prov Corps Hosp Chinese Peoples Armed Pol, Dept Rehabil Med & Physiotherapy, 8 Jiangdu South Rd, Yangzhou 225003, Jiangsu, Peoples R China
[3] Jiangdu Peoples Hosp, Dept Neurosurg, Yangzhou, Jiangsu, Peoples R China
关键词
Breast cancer and brain metastases; whole-brain radiotherapy; chemotherapy; prognosis; quality of life; P-GLYCOPROTEIN; TRASTUZUMAB; THERAPY;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective: This paper aims to explore the effects of whole-brain radiotherapy (WBRT) and chemotherapy on patients with breast cancer and brain metastases (BCBM) and on their quality of life (QOL). Methods: Fifty-eight patients with BCBM were recruited as the study cohort and randomly divided into a control group and a study group. The patients in the control group underwent WBRT. Their radiotherapy scheme was as follows: the fractionation was 2.0 Gy/time, and the total dosage was 60 Gy, 5 times/week for 6 weeks. The patients in the study group underwent WBRT plus chemotherapy. Their radiotherapy scheme was the same as the control group's. Their chemotherapy scheme was as follows: carboplatin (0.3 g/m(2)) was intravenously injected every day, and the injection was repeated once four weeks later. After the treatment, the patients' adverse reactions were compared between the two groups. Their Karnofsky Performance Status (KPS) scores were also compared to analyze the effects of WBRT plus chemotherapy and radiotherapy alone on the patients' survival statuses. Results: After the treatment, the adverse reactions were not significantly different in the two groups (P>0.05). The objective remission rate in the study group was 79.31%, which was higher than the 34.48% rate in the control group (P=0.001). According to the KPS scores, the QOL of the patients in the study group was significantly improved after the treatment, and the difference was statistically significant compared with the QOL in the control group (P<0.001). The overall survival and the progression-free survival in the study group were longer than they were in the control group (both P<0.01). Conclusion: Compared with WBRT alone, WBRT plus chemotherapy is safe and markedly effective in treating patients with BCBM, and it can improve their QOL and prolong their survival times. Therefore, this combined treatment is worthy of clinical application and further research.
引用
收藏
页码:1250 / 1257
页数:8
相关论文
共 50 条
  • [1] Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients
    Cyrus Chargari
    Youlia M. Kirova
    Véronique Diéras
    Pablo Castro Pena
    Francois Campana
    Paul H. Cottu
    JeanYves Pierga
    Alain Fourquet
    [J]. Journal of Neuro-Oncology, 2009, 93 (3) : 385 - 385
  • [2] Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients
    Cyrus Chargari
    Youlia M. Kirova
    Véronique Diéras
    Pablo Castro Pena
    Francois Campana
    Paul H. Cottu
    JeanYves Pierga
    Alain Fourquet
    [J]. Journal of Neuro-Oncology, 2009, 93
  • [3] Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients
    Chargari, Cyrus
    Kirova, Youlia M.
    Dieras, Veronique
    Pena, Pablo Castro
    Campana, Francois
    Cottu, Paul H.
    Pierga, JeanYves
    Fourquet, Alain
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2009, 93 (03) : 379 - 384
  • [4] Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases
    Niwinska, A.
    Murawska, M.
    Pogoda, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Breast Cancer Subtypes and Response to Systemic Treatment After Whole-Brain Radiotherapy in Patients With Brain Metastases
    Niwinska, Anna
    Murawska, Magdalena
    Pogoda, Katarzyna
    [J]. CANCER, 2010, 116 (18) : 4238 - 4247
  • [6] A Phase 2 Trial of Whole-brain Radiotherapy Combined With Intravenous Chemotherapy in Patients With Brain Metastases From Breast Cancer
    Cassier, Philippe A.
    Ray-Coquard, Isabelle
    Sunyach, Marie-Pierre
    Lancry, Laurence
    Guastalla, Jean-Paul
    Ferlay, Celine
    Gomez, Frederic
    Cure, Herve
    Lortholary, Alain
    Claude, Line
    Blay, Jean-Yves
    Bachelot, Thomas
    [J]. CANCER, 2008, 113 (09) : 2532 - 2538
  • [7] Whole-brain radiation therapy in breast cancer patients with brain metastases
    Cyrus Chargari
    François Campana
    Jean-Yves Pierga
    Lionel Védrine
    Damien Ricard
    Sylvestre Le Moulec
    Alain Fourquet
    Youlia M. Kirova
    [J]. Nature Reviews Clinical Oncology, 2010, 7 : 632 - 640
  • [8] Whole-brain radiation therapy in breast cancer patients with brain metastases
    Chargari, Cyrus
    Campana, Francois
    Pierga, Jean-Yves
    Vedrine, Lionel
    Ricard, Damien
    Le Moulec, Sylvestre
    Fourquet, Alain
    Kirova, Youlia M.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (11) : 632 - 640
  • [9] Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases
    Addeo, Raffaele
    Sperlongano, Pasquale
    Montella, Liliana
    Vincenzi, Bruno
    Carraturo, Marco
    Iodice, Patrizia
    Russo, Paola
    Parlato, Ciro
    Salzano, Antonio
    Cennamo, Gregorio
    Lombardi, Angela
    Sperlongano, Rossella
    Del Prete, Salvatore
    Caraglia, Michele
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (04) : 603 - 609
  • [10] Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases
    Raffaele Addeo
    Pasquale Sperlongano
    Liliana Montella
    Bruno Vincenzi
    Marco Carraturo
    Patrizia Iodice
    Paola Russo
    Ciro Parlato
    Antonio Salzano
    Gregorio Cennamo
    Angela Lombardi
    Rossella Sperlongano
    Salvatore Del Prete
    Michele Caraglia
    [J]. Cancer Chemotherapy and Pharmacology, 2012, 70 : 603 - 609